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Abstract
 
Interleukin-1
 
b
 
–converting enzyme (ICE, caspase-1) regulates key steps in inflammation and
immunity, by activating the proinflammatory cytokines interleukin (IL-)1
 
b
 
 and IL-18, or me-
diating apoptotic processes. We recently provided evidence for the regulation of caspase-1 ac-
tivity via an endogenous inhibitor expressed by human vascular smooth muscle cells (SMCs)
(Schönbeck, U., M. Herzberg, A. Petersen, C. Wohlenberg, J. Gerdes, H.-D. Flad, and H.
 
Loppnow. 1997. 
 
J. Exp. Med.
 
 185:1287–1294). However, the molecular identity of this en-
dogenous inhibitor remained undefined. We report here that the serine proteinase inhibitor
(serpin) PI-9 accounts for the endogenous caspase-1 inhibitory activity in human SMCs and
prevents processing of the enzyme’s natural substrates, IL-1
 
b
 
 and IL-18 precursor. Treatment
of SMC lysates with anti–PI-9 antibody abrogated the caspase-1 inhibitory activity and copre-
cipitated the enzyme, demonstrating protein–protein interaction. Furthermore, PI-9 antisense
oligonucleotides coordinately reduced PI-9 expression and promoted IL-1
 
b
 
 release. Since
SMCs comprise the majority of cells in the vascular wall, and because IL-1 is implicated in
atherogenesis, we tested the biological validity of our in vitro findings within human atheroma
in situ. The unaffected arterial wall contains abundant and homogeneously distributed PI-9. In
human atherosclerotic lesions, however, PI-9 expression correlated inversely with immunore-
active IL-1
 
b
 
, supporting a potential role of the endogenous caspase-1 inhibitor in this chronic
inflammatory disease. Thus, our results provide new insights into the regulation of this enzyme
involved in immune and inflammatory processes of chronic inflammatory diseases, and point to
an endogenous antiinflammatory action of PI-9, dysregulated in a prevalent human disease.
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Introduction
 
IL-1
 
b
 
–converting enzyme (ICE,
 
1
 
 caspase-1) (1, 2) is the
prototype of a family of cysteine proteases termed caspases,
sharing the active site cysteine and aspartate binding clefts
(3). The biological function of caspase-1 was originally
thought to be restricted to the maturation process of IL-1
 
b
 
,
a central mediator in the cytokine network (4–7). Pro-
teolytic maturation of the inactive, 33-kD IL-1
 
b
 
 precursor
(proIL-1
 
b
 
) into the 17-kD, biologically functional form
(8–11) results from cleavage at the Asp
 
116
 
–Ala
 
117
 
 site (1, 2,
12–14). However, recent studies revealed that caspase-1
mediates processes relevant to immune and inflammatory
reactions, in addition to IL-1
 
b
 
 activation. The enzyme has
been implicated in the activation of another inflammatory
cytokine, IL-18, originally termed IFN-
 
g
 
 inducing factor
(IGIF) (15–20). Similar to IL-1
 
b
 
, IL-18 is expressed as an
inactive precursor (24 kD), requiring proteolytic conver-
sion via caspase-1 into the active, 18-kD form (21). The
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Abbreviations used in this paper:
 
 CrmA, cytokine response modifier A;
 
EC, endothelial cell; FBS, fetal bovine serum; ICE, IL-1
 
b
 
–converting
enzyme; IT, insulin/transferrin; M
 
f
 
, macrophage(s); PI, proteinase inhib-
itor; SMC, smooth muscle cell. 
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biological function of IL-18 was originally thought to be
restricted to the induction of another inflammatory cyto-
kine, IFN-
 
g
 
, which has well-known roles in inflammation
and Th1 immune responses (18, 20, 22). However, recent
work indicated a much broader role for IL-18 in immunity
and inflammation, mediating the expression of other proin-
flammatory cytokines, certain chemokines, and Fas ligand
(16). In addition to the activation of proinflammatory me-
diators, caspase-1 is the prototype of a family of enzymes
implicated in the control of apoptosis. Although the exact
function of caspase-1 is controversial, this enzyme may par-
ticipate in programmed cell death (23–27).
Since caspase-1–mediated processing of IL-1
 
b
 
 and IL-18
as well as the promotion of apoptosis are considered crucial
processes in chronic inflammatory diseases, the (physiologic
and therapeutic) regulation of caspase-1 activity has gar-
nered considerable interest in recent years. The enzyme was
originally isolated and cloned from cells of the monocytic
lineage (1, 2, 12–14). However, not surprisingly given the
widespread expression of its substrate, IL-1
 
b
 
 precursor (4),
other cell types also express caspase-1, including endothelial
cells (ECs) and smooth muscle cells (SMCs), fibroblasts, and
epithelial and epidermal cells (28–30). Typically, caspase-1
is synthesized as an inactive 45-kD precursor and autocata-
lytically processed to form an active homodimeric complex
consisting of the 10- and 20-kD subunit, (p20/p10)
 
2 
 
(31, 32).
However, detection of mature immunoreactive caspase-1
protein does not always correspond to its biological activity
(29, 33). Indeed, regulation of caspase-1 activity remains
obscure. Early studies on modulators of caspase-1 activity
revealed that besides synthetic peptides (1, 34), certain viral
proteins can block the enzyme’s activity (35–37). Cowpox
virus effectively diminished inflammatory responses against
viral infection in the chick via a specific inhibitor of
caspase-1, encoded by the cytokine response modifier A
(CrmA) gene (35). Previously, we and others have pro-
vided evidence for the presence of a human-derived en-
dogenous inhibitor (29, 33). We described a constitutively
expressed, heat-labile, cell-associated caspase-1 inhibitory
activity in human vascular SMCs (29), the most abundant
cell type in arteries and a central participant in the patho-
genesis of vascular diseases (38, 39).
The viral caspase-1 inhibitor CrmA belongs to the family
of serine proteinase inhibitors, termed serpins (40). Recently,
we cloned the human serpin PI-9. This protein shares 54%
identity with residues found in the reactive center loop of the
cowpox virus CrmA serpin (41, 42) and, as recently de-
scribed, inhibits granzyme B–mediated apoptosis as well as
caspase-1–mediated cleavage of synthetic substrates (43, 44).
PI-9 shares several biochemical characteristics with the en-
dogenous caspase-1 inhibitory activity previously identified in
vascular SMCs, including the constitutive and cell-associated
expression, as well as a molecular mass of 42 kD (41). Thus,
we tested the hypothesis that PI-9 accounts for the endoge-
nous caspase-1 inhibitory activity in human vascular SMCs.
We report here that human vascular SMCs constitutively
express PI-9, and that this serpin accounts for the endogenous
caspase-1 inhibitory activity in these cells, preventing process-
 
ing of the native caspase-1 substrates IL-1
 
b
 
 and IL-18 precur-
sor. The inhibitory activity of PI-9 requires protein–protein
interaction with the enzyme. Since vascular SMCs comprise
the most abundant cell type in arteries, and IL-1 likely partic-
ipates in the pathogenesis of vascular diseases (38, 39), we fur-
ther analyzed the expression of PI-9 within undiseased and
atherosclerotic human arteries. The homogenous, abundant
expression of PI-9 in normal tissue contrasts with its pattern
of expression in atherosclerotic lesions. Within human ather-
oma, the inhibitor localized inversely with caspase-1 and IL-
1
 
b
 
 expression. Our results suggest a novel endogenous antiin-
flammatory function of PI-9, and indicate dysregulation of
this control mechanism in an important human disease.
 
Materials and Methods
 
Materials.
 
Human recombinant mature IL-1
 
b
 
 was obtained
from Endogen. Human recombinant precursor IL-1
 
b
 
 (proIL-1
 
b
 
) was
purchased from Cistron. Recombinant human PI-8 and PI-9, as well
as the respective polyclonal antibodies (raised against the respective
full-length protein; affinity-purified), were generated as described
previously (41). The anti–IL-1
 
b
 
 antibody was obtained from Up-
state Biotechnology. The anti-ICE
 
P20
 
 antibody was provided by
Santa Cruz biotechnology. Control mouse and rabbit Ig were ob-
tained from Sigma Chemical Co. Recombinant human caspase-1
was provided by Dr. Nancy Thornberry (Merck Laboratories,
Rahway, NJ). Recombinant human caspase-3 was purchased from
Transduction Laboratories. Gelsolin was provided by Dr. T. Azuma
(Brigham and Women’s Hospital). The synthetic tetrapeptide fluo-
rogenic caspase-3 substrate (Ac-DEVD-AMC) and the synthetic
caspase inhibitor DEVD-CHO were obtained from PharMingen.
 
Cell Isolation and Culture.
 
Human vascular SMCs were iso-
lated from human saphenous veins by explant outgrowth (45),
and cultured in DMEM (BioWhittaker) supplemented with 1%
 
l
 
-glutamine (BioWhittaker), 1% penicillin/streptomycin (Bio-
Whittaker), and 10% fetal bovine serum (FBS; Atlanta Biologicals).
Cells were subcultured after trypsinization (0.5% trypsin [Wor-
thington Biochemicals], 0.2% EDTA [EM Science]), in 75-cm
 
2
 
 cul-
ture flasks (Becton Dickinson) and used throughout passages two
to four. SMCs were cultured 24 h before the experiment in IT
(insulin/transferrin) medium lacking FBS, as described previously
(46). SMCs were characterized by immunostaining with anti-
SMC 
 
a
 
-actin antibody (Enzo Diagnostics Inc.).
Mononuclear phagocytes were isolated by density gradient
centrifugation (47), using Lymphocyte Separation Medium (Or-
ganon-Teknika), and subsequent counterflow elutriation from
freshly prepared human PBMCs obtained from leukopacs of healthy
donors (provided by Dr. B. Rollins, Dana-Farber Cancer Insti-
tute, Boston, MA). The purity of monocytes/macrophages was
 
$
 
96%, as determined by FACS
 
®
 
 analysis (anti–human CD68
mAb FITC; PharMingen).
As the source of IL-18, THP-1 cells were obtained from Amer-
ican Type Culture Collection (TIB-202) and were maintained in
RPMI 1640 with 2.5 g/liter glucose, 1 mM Hepes, 1 mM sodium
pyruvate, 50 
 
m
 
M 2-ME, containing 10% human serum. To obtain
lysates, cells were pelleted (500 
 
g
 
, 10 min), resuspended in 10
 
6
 
cells/ml sterile water, and exposed to three freeze–thaw cycles.
Culture media and FBS contained 
 
,
 
40 pg endotoxin/ml as
determined by chromogenic Limulus amebocyte assay (QLC-
1000; BioWhittaker).
 
Processing Assay.
 
For processing, recombinant human proIL-1
 
b
 
(20 nM), proIL-18 (equivalent to 50,000/ml cells), or gelsolin was 
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incubated for 30 min with recombinant human caspase-1 (15 nM),
native caspase-1 obtained from lysates of monocyte cultures (ob-
tained by three freeze–thaw cycles), or recombinant human caspase-3
(25 nM) at 37
 
8
 
C in a final volume of 50 
 
m
 
l processing buffer (10
mM Hepes, 2 mM dithiothreitol, 5% glycerol; final concentrations).
To analyze inhibition of processing, the indicated concentrations of
PI-8 or PI-9 were preincubated with either the enzyme (recombi-
nant or monocyte-derived caspase-1 or caspase-3) or the substrate
(proIL-1
 
b
 
, proIL-18, or gelsolin) for the respective duration. For
control purposes, a synthetic caspase inhibitor (DEVD-CHO) was
used instead of the serpin. Processing was stopped by heating the
samples (10 min, 95
 
8
 
C) in 10 
 
m
 
l SDS-PAGE (5
 
3
 
) sample buffer
(0.2 M Tris, 5% glycerol, 0.1% SDS, 3% 
 
b
 
-ME, 0.1 mg/ml bro-
mophenol blue; final concentrations). Finally, samples were applied
to SDS-PAGE and developed by either Coomassie stain (gelsolin)
or Western blot analysis using the anti–human IL-1
 
b
 
 or IL-18 anti-
body (1:1,000). To analyze the caspase-1 inhibitory activity in
SMCs, culture lysates were harvested in processing buffer. After
three freeze–thaw cycles, the lysates were preincubated with the re-
combinant enzyme (15 nM, 30 min, 37
 
8
 
C) before the IL-1
 
b
 
 or IL-
18 precursor (20 nM) was added for an additional 30 min.
For immunoprecipitation experiments, lysates of SMC cultures
were harvested and incubated with nonimmune rabbit serum (24 h,
4
 
8
 
C; Vector Laboratories) to preclear the samples. The cell ex-
tracts were immunoprecipitated with the specific anti–PI-9 anti-
body (6 h, 4
 
8
 
C) and pelleted by subsequent addition of goat anti–
rabbit IgG (18 h, 4
 
8
 
C; Jackson ImmunoResearch Laboratories) as
well as protein A–Sepharose beads (2 h, 4
 
8
 
C; Amersham Pharma-
cia Biotech). Supernatants (corresponding to PI-9–depleted ly-
sates of SMC cultures) and precipitates were either resuspended in
SDS-PAGE loading buffer (200 mmol/liter Tris, 5% glycerol,
0.1% SDS, 3% 
 
b
 
-ME, 0.1 mg/ml bromophenol blue), separated
by SDS-PAGE, and analyzed by Western blotting, or were resus-
pended in processing buffer and applied to the processing assay.
 
Antisense Experiments.
 
Antisense PI-9 (5
 
9
 
-GAAAGAGTTT-
CCATGATGCAG-3
 
9
 
) and control (5
 
9
 
-TTACCGCGCCGTA-
GACGGGCA-3
 
9
 
) phosphorothioate oligodeoxynucleotides were
synthesized and purified via reverse-phase HPLC by Integrated
DNA Technologies, Inc. Subconfluent cultures of human vascular
SMCs were washed twice with DMEM and subsequently incu-
bated with DMEM containing Lipofectin (1 
 
m
 
g/ml; Life Tech-
nologies, Inc.) and the respective oligodeoxynucleotide (5 
 
m
 
M).
Cells were maintained in DMEM for 72 h, before the 24-h stim-
ulation (TNF-
 
a
 
, 50 ng/ml). Finally, lysates and supernatants of these
SMC cultures were harvested and applied to Western blot analysis
for PI-9 or caspase-1, and IL-1
 
b
 
 ELISA, respectively.
 
Western Blot Analysis.
 
Cell extracts, equilibrated by total pro-
tein (25 
 
m
 
g total protein/lane), culture supernatants, or processing
assay preparations were separated by standard SDS-PAGE under
reducing conditions and blotted to polyvinylidene difluoride
membranes (Bio-Rad) using a semidry blotting apparatus (0.8
mA/cm
 
2
 
, 30 min; Bio-Rad). Blots were blocked and first and
second mAbs were diluted in 5% defatted dry milk/PBS/0.1%
Tween 20. After 1 h of incubation with the respective primary
antibody, blots were washed three times (PBS/0.1% Tween) and
the secondary, peroxidase-conjugated, goat anti–mouse or goat
anti–rabbit antibody (Jackson ImmunoResearch Laboratories) was
added for an additional 1 h. Finally, the blots were washed (20
min, PBS/0.1% Tween 20) and immunoreactive proteins were
visualized using the Western blot chemiluminescence system
(NEN). Densitometric analysis of immunoreactive bands em-
ployed Image-Pro
 
®
 
 software (Media Cybernetics) applied to digi-
tal images of the respective Western blots.
 
ELISA.
 
Release of IL-1
 
b
 
 from human vascular SMCs was
measured by ELISA, following the recommendations of the man-
ufacturer (Endogen). In brief, SMC supernatants (200 
 
m
 
l) ob-
tained from the antisense experiments were added for 1 h to 96-
well modules (Nunc) coated with the capturing antibody (1 
 
m
 
g/
ml, 4
 
8
 
C overnight). Subsequently the plates were washed (PBS/
0.1% Tween) three times, and the respective biotin-labeled de-
tecting mouse anti–human IL-1
 
b
 
 mAb (0.5 
 
m
 
g/ml) was added
(1 h). Finally, wells were incubated for 30 min with alkaline
phosphatase (Vectastain ABC kit, AK-500; Vector Laboratories)
and were washed four times. Antibody binding was detected by
adding 
 
p
 
-nitrophenyl phosphate (1.39 mg/ml; Sigma Chemical
Co.), and absorbance was measured at 405 nm in a Dynatech
plate reader. The amount of cytokine detected was calculated
from a standard curve prepared from recombinant mature IL-1
 
b
 
.
Samples were assayed in triplicate. Error bars represent SD.
 
Immunohistochemistry.
 
Surgical specimens of human carotid
atheroma and aorta were obtained by protocols approved by the Hu-
man Investigation Review Committee at the Brigham and Women’s
Hospital. Nonatherosclerotic tissue was obtained from both carotid
arteries and aortae, whereas atherosclerotic tissue employed only ca-
rotid specimen. Serial cryostat sections (5 
 
m
 
m) were cut, air dried
onto microscope slides (Fisher Scientific), and fixed in acetone at
 
2
 
20
 
8
 
C for 5 min. Sections were preincubated with PBS containing
0.3% hydrogen peroxidase activity. The sections were then incu-
bated (30 min) with primary or control (mouse myeloma protein
MOPC-21; Sigma Chemical Co.) antibody, diluted in PBS supple-
mented with 5% appropriate serum. The subsequent processing was
performed according to the manufacturer’s recommendations (Uni-
versal Dako LSAB kit; Dako). Antibody binding was visualized with
3-amino-9-ethyl carbazole (Vector) according to the recommenda-
tions provided by the supplier. For colocalization of caspase-1 with
PI-9, or either molecule with the respective cell type, double-immu-
nofluorescence staining was performed. The goat anti–human
ICE
 
P20
 
 antibody (1:100) was applied for 90 min followed by biotiny-
lated anti–mouse secondary antibody for 45 min and Texas red–con-
jugated streptavidin (Amersham Pharmacia Biotech). Subsequent to
application of the avidin/biotin blocking kit (Vector Laboratories),
rabbit anti–human PI-9 antibody (1:50), anti–muscle actin mAb for
SMCs (Enzo Diagnostics), anti-CD31 mAb for ECs (1:400; Dako),
or anti-CD68 mAb for macrophages (M
 
f
 
, 1:600; Dako) was added,
and sections were incubated overnight at 4
 
8
 
C. Subsequently, the ap-
propriate secondary antibodies were applied for 30 min followed by
streptavidin-FITC (Amersham Pharmacia Biotech).
 
Biochemical Analysis of Human Atherosclerotic Lesions.
 
Frozen tis-
sue from nonatherosclerotic and atheromatous specimens, dichot-
omized by morphological criteria as stable or vulnerable plaques
as described previously (48), were homogenized (Ultra-turrax T 25;
IKA-Labortechnik) and lysed (0.3 g tissue/ml lysis buffer: 10 mM
sodium phosphate, 150 mM sodium chloride, 1% Triton X-100,
0.1% SDS, 0.5% sodium deoxycholate, 0.2% sodium azide). The
lysates were clarified (13,000 
 
g
 
, 15 min), and the protein concen-
tration for each tissue extract as well as for the cell culture samples
was determined using a bicinchoninic acid (BCA) protein assay
according to the instructions of the manufacturer (Pierce Chemi-
cal Co.). 50 
 
m
 
g total protein was applied to Western blot analysis.
 
Results
 
The Serpin PI-9 Inhibits Processing of the IL-1
 
b 
 
and IL-18
Precursor by Native or Recombinant Caspase-1.
 
To determine
whether PI-9 indeed inhibits processing of the native sub- 
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strate by caspase-1, a processing assay was established in
which the enzyme cleaves the 33-kD recombinant human
IL-1
 
b
 
 precursor (proIL-1
 
b
 
) into the expected (1, 29, 49)
predominant 28- and 17-kD (as well as an occasional 25-
kD) forms, as detected by Western blot analysis (Fig. 1 A).
The inhibitory capacity of PI-9 was explored by addition
of the serpin to the assay at various time points, i.e., allow-
ing preincubation with either the enzyme or the substrate.
When added after coincubation of proIL-1
 
b
 
 with native
(monocyte-derived) or recombinant caspase-1, PI-9 did
not affect processing (Fig. 1 A). However, simultaneous in-
cubation of PI-9, enzyme, and substrate in this assay
yielded partial inhibition of proIL-1
 
b processing, and when
preincubated with the enzyme, PI-9 completely inhibited
processing of the IL-1b precursor by native or recombinant
caspase-1 (Fig. 1, A and B). In addition to the time of pre-
incubation, inhibition of caspase-1 processing activity by
PI-9 depended on the temperature during preincubation,
requiring preincubation at 378C (using $100 nM PI-9) for
maximal inhibition and showing diminished inhibitory ac-
tivity at room temperature or 48C. Partial inhibition oc-
curred after times of preincubation as short as 5 min. In
contrast to PI-9, a related serpin family member, PI-8 (50;
as well as the more distant relative ovalbumin), did not af-
fect caspase-1 activity, even when added at high concentra-
tions (up to 200 mg/ml, <5 mM) or preincubated for ex-
tended periods of time (up to 24 h). Interestingly, PI-9
differentially inhibited the processing into the two predom-
inant products, the 28- and 17-kD forms (Fig. 2). Com-
plete inhibition of processing into the mature 17-kD form
of IL-1b required 4–6 mg/ml (<100–150 nM) PI-9 (n 5
5; with an IC50 < 57 6 16 nM), whereas inhibition of pro-
cessing into the 28-kD form required higher concentra-
tions (.20 mg/ml; .500 nM) of PI-9 (n 5 5; with an
IC50 < 272 6 69 nM). Partial inhibition occurred when
using as little as 0.5–1 nM PI-9. Similar concentration- and
time-dependencies of the inhibition of caspase-1 processing
activity were obtained when a second native substrate for
Figure 1. The human serpin PI-9 inhibits native and recombinant
caspase-1 processing activity. (A) Human recombinant PI-9 (100 nM) was
either preincubated for 30 min (230) with native, monocyte-derived
(Mf-Lysates; equivalent to 106 Mf/ml) or recombinant (rec.) caspase-1
(15 nM), applied simultaneously (0), or added 30 min after incubation
(130) of proIL-1b (20 nM) with the enzyme for 30 min at 378C in a final
volume of 50 ml processing buffer. (B) Human recombinant caspase-1 (15
nM, top) or human recombinant IL-1b precursor (20 nM, bottom) was
preincubated for 30 min with the indicated concentrations of PI-9, before
application to the processing assay. Processing was stopped by heating the
samples in 10 ml SDS-PAGE sample buffer. The preparations were ana-
lyzed by 15% SDS-PAGE and subsequent Western blot analysis using
anti–human IL-1b. For control purposes, recombinant mature (mIL-1b,
20 nM) and precursor (pIL-1b, 20 nM) IL-1b were applied. The positions
of the molecular weight markers are indicated on the left (in kD). Similar
data were obtained in three (A) or five (B) independent experiments.
Figure 2. PI-9 concentration-dependently inhibits recombinant
caspase-1 processing activity. (A) Human recombinant caspase-1 (15 nM)
was preincubated with the indicated concentrations of PI-9 for 30 min at
378C, before being added for 30 min (378C) to proIL-1b (20 nM) in 50
ml processing buffer. Reactions were stopped by heating the samples in
10 ml SDS-PAGE sample buffer, and the preparations were applied to
15% SDS-PAGE and subsequent Western blot analysis using anti–human
IL-1b. For control purposes, recombinant mature and precursor IL-1b
were applied in combination (m/pIL-1b, both at 20 nM). The positions
of the molecular weight markers are indicated on the left (in kD). (B)
Densitometric analysis of immunoreactive cleavage products obtained in
the processing assays described in A. The IC50 was determined in refer-
ence to untreated recombinant proIL-1b (20 nM, 33-kD form) or mature
IL-1b (20 nM, 17-kD form). Similar data were obtained in eight inde-
pendent experiments.1539 Young et al.
the enzyme, IL-18, was used (Fig. 3). Interestingly, inhibi-
tion of the IL-18 processing activity also required the pre-
incubation of the enzyme rather than the substrate for opti-
mal effectiveness.
We further tested the specificity of the PI-9–mediated
inhibition of caspase-1 processing activity by analyzing
whether the serpin inhibits other caspases. Neither PI-9
nor PI-8 inhibited caspase-3 activity, using either a native
substrate, gelsolin (51), in a processing assay similar to that
used for analysis of caspase-1 activity, or a fluorogenic syn-
thetic peptide (data not shown).
The Serpin PI-9 Accounts for the Endogenous Caspase-1 In-
hibitory Activity of Human Vascular SMCs. To extend the
above observations, obtained with recombinant material, to
extracts of human vascular SMCs, previously found to ex-
press a heretofore unidentified caspase-1 inhibitory activity
(29; see also Fig. 5 A), we analyzed PI-9 expression in these
cells. SMCs indeed expressed immunoreactive PI-9 consti-
tutively as a cell-associated immunoreactive band with an
apparent molecular mass of 42 kD (Fig. 4), resembling the
biochemical characteristics described for the endogenous
caspase-1 inhibitory activity. Stimulation with either IL-
1b, TNF-a, or IFN-g, or combinations thereof, affected
neither the cell-associated, constitutive expression of PI-9
nor the release of the serpin. In contrast, constitutive ex-
pression of PI-9 in freshly isolated peripheral blood mono-
cytes was diminished after either stimulation with LPS or
culture-mediated differentiation (Fig. 4 B).
Immunoprecipitation of SMC lysates with the anti–
human PI-9 antibody depleted coordinately the serpin (data
not shown) and the caspase-1 inhibitory activity, as dem-
onstrated by the finding that anti–PI-9–treated SMC lysates
no longer prevented cleavage of the IL-1b precursor (Fig.
5 A). Interestingly, the anti–PI-9 immunoprecipitate con-
tained both PI-9 (data not shown) and caspase-1 (Fig. 5 B).
Control experiments revealed that the anti–PI-9 antibody
does not cross-react with recombinant caspase-1. The pre-
cipitate did not contain proIL-1b processing activity (data
not shown), indicating complete inhibition of endoge-
nously expressed caspase-1 via endogenous PI-9. Neither
anti–PI-8 (Fig. 5 B) nor nonimmune rabbit control IgG
(data not shown) immunoprecipitated caspase-1.
Inhibition of PI-9 Expression Induces the Release of IL-1b
from Human Vascular SMCs. To explore further the po-
tential importance of PI-9–mediated regulation of caspase-1
processing activity, we treated cultures of unstimulated or
TNF-a–stimulated vascular SMCs with PI-9 antisense oli-
gonucleotides. This treatment coordinately reduced PI-9
expression (Fig. 6, top) and augmented the release of active
IL-1b from TNF-a–stimulated cultures (Fig. 6, middle).
As SMCs retain IL-1b intracellularly under usual condi-
tions (52, 53), this finding demonstrates that diminished
expression of endogenous PI-9 indeed allows maturation of
the IL-1b precursor in intact cells. PI-9 antisense treatment
did not affect endogenous caspase-1 expression (Fig. 6,
bottom), demonstrating specificity of the observed alter-
ations in IL-1b release.
Figure 3. The human serpin PI-9 inhibits processing of the IL-18 pre-
cursor by caspase-1. Human recombinant caspase-1 (15 nM, top) or hu-
man recombinant IL-18 precursor (equivalent to 50,000/ml THP.1
cells) was preincubated for 30 min (378C) with the indicated concentra-
tions of PI-9, before either the substrate (IL-18, top) or the enzyme
(bottom) was added (30 min, 378C). Processing was stopped by heating
the samples in 10 ml SDS-PAGE sample buffer. Samples were analyzed
by 15% SDS-PAGE and subsequent Western blot analysis using anti–
human IL-18. For control purposes, THP.1 lysate (THP.1; equivalent to
106 cells/ml) was applied. The positions of the molecular weight markers
are indicated on the left (in kD). Similar data were obtained in three in-
dependent experiments.
Figure 4. Human vascular SMCs express PI-9 constitutively and in a
cell-associated manner. (A) Lysates of SMCs, cultured for 24 h in IT me-
dium in the absence (None) or presence of the respective concentrations
of human recombinant mature IL-1b/TNF-a, were obtained by three
freeze–thaw cycles. Lysates (Lys), equilibrated for total protein (50 mg/
lane), as well as supernatants (SN, 50 ml; obtained from cultures stimu-
lated with 30 ng/ml IL-1b/TNF-a) were analyzed by Western blotting
with anti–human PI-9 antibody. (B) Similarly, lysates of peripheral blood
mononuclear cells cultured for 1, 3, or 10 d (50 mg total protein/lane)
were applied to Western blot analysis using anti–human PI-9 antibody.
Recombinant PI-9 (recPI-9, 20 nM) was applied for control purposes.
The positions of the molecular weight markers are indicated on the left
(in kD). Similar data were obtained in three independent experiments.1540 Inhibition of Caspase-1 by the Serpin PI-9
Differential Expression of PI-9, Caspase-1, and IL-1b in
Nonaffected and Atherosclerotic Arteries. Since SMCs com-
prise the most abundant cell type in arteries and participate
in vascular diseases, e.g., via expression of proinflammatory
cytokines such as IL-1, we examined the expression of PI-9
in normal (n 5 5) tissue and colocalized its expression
with that from caspase-1 and IL-1b within atherosclerotic
(n 5 5) arteries. SMCs in normal arteries had low, but de-
tectable, levels of caspase-1 (Fig. 7 A), which colocalized
with abundant and homogeneously distributed PI-9 (Fig. 7
B). Normal vessels did not stain for IL-1b (Fig. 7 C). Ex-
pression of PI-9 was less intense and homogenous within
atherosclerotic lesions compared with unaffected arterial
tissue. Furthermore, PI-9 and caspase-1 localize inversely
in atheroma. Caspase-1 (Fig. 7 D) as well as IL-1b (Fig. 7
F) localized most prominently in the macrophage-enriched
shoulder region, whereas PI-9 localized most prominently
in the SMC-enriched fibrous cap of the atherosclerotic
plaque (Fig. 7 E), further demonstrated by immunofluores-
cence double labeling for PI-9 (green) and caspase-1 (red)
(Fig. 7 G). The caspase-1 signal predominated over PI-9 in
the more macrophage-rich shoulder area, whereas in the
SMC-enriched fibrous cap PI-9 staining exceeded immu-
nodetectable caspase-1. These findings corroborate with the
reduced constitutive or absent expression of PI-9 in acti-
vated and/or differentiated mononuclear phagocytes (Fig.
4 H). In accordance with the immunohistochemical find-
ings, Western blot analysis further demonstrated dimin-
ished total PI-9 concentrations in protein extracts of ath-
erosclerotic lesions compared with unaffected tissue (Fig. 7
H). Moreover, Western blot analysis for PI-9 correlated
inversely with enhanced immunoreactive IL-1b levels
(Fig. 7 H). Notably, mature IL-1b was found primarily in
extracts of atherosclerotic lesions, with morphologic char-
acteristics of those prone to rupture and thus likely to cause
acute clinical complications (defined by a large lipid core
and thin fibrous cap, as described previously [48, 54]).
Discussion
Increasing evidence suggests a critical role of caspase-1 in
inflammation, linking enhanced caspase-1 activity with the
progression of various diseases, e.g., via the activation of the
proinflammatory cytokine IL-1b and furthermore by pro-
moting apoptosis. Despite the scientific interest in and po-
tential importance of caspase-1 in inflammatory and im-
mune processes, little is known regarding regulation of the
enzyme’s activity. This study identifies the serpin PI-9 as an
Figure 5. Human vascular SMCs
depleted of endogenous PI-9 lack
caspase-1 inhibitory activity. Human
vascular SMCs were cultured for 24 h
serum-free in IT medium, before
being incubated for 24 h with fresh
medium in the absence (None) or
presence of human recombinant IL-
1b/TNF-a (10/50 ng/ml). (A) Cul-
ture lysates of SMCs (equivalent to
107 cells/ml) were incubated with
the anti–human PI-9 antibody (24 h,
48C) and subsequently precipitated
with protein A–Sepharose (500 g, 10
min). The remaining supernatants
were incubated with human recom-
binant caspase-1 (15 nM; 1 h, 378C)
before being added to recombinant IL-1b precursor (20 nM) for 30 min at 378C, and application to Western blot analysis using anti-human IL-1b. Com-
bined mature (20 nM) and precursor (20 nM) IL-1b were applied as controls (m/pIL-1b). (B) Culture lysates of SMCs (equivalent to 107 cells/ml) were
incubated with either affinity- or protein A–purified anti–human PI-9 or affinity-purified PI-8 antibody (24 h, 48C), and subsequently precipitated with
protein A–Sepharose (500 g, 10 min). The precipitates were applied to Western blot analysis using anti–human ICEP20. The positions of the molecular
weight markers are indicated on the left (in kD). Similar data were obtained in three independent experiments, using SMC isolates of five different donors.
Figure 6. PI-9 antisense treatment induces the release of IL-1b into the
supernatant of vascular SMC cultures. Cultures of SMCs were treated with
lipofectin (1 mg/ml; GIBCO BRL) and PI-9 antisense or scrambled (Scr)
phosphorothioate oligodeoxynucleotides for 72 h in the absence (None)
or presence of recombinant TNF-a (50 ng/ml) during the last 24 h. Ly-
sates of these cultures were analyzed by Western blotting using anti–PI-9
(top) or anti–caspase-1 (bottom), whereas supernatants were assayed for
IL-1b by ELISA (middle), using recombinant IL-1b (recIL-1b) as stan-
dard. The positions of the molecular weight markers are indicated on the
left (in kD). Similar data were obtained in three independent experiments.1541 Young et al.
endogenous caspase-1 inhibitor in human vascular SMCs in
vitro, and provides evidence that an imbalance between PI-9
and caspase-1 expression prevails at sites of chronic inflam-
matory diseases, such as atherosclerosis, in vivo.
Early studies of caspase-1 expression revealed mechanisms
of autocatalytic activation of the inactive 45-kD precursor
form, via intermediate forms, into the enzymatically active
(p20/p10)2 homodimer (1, 2, 31, 32). Further studies dem-
onstrated that caspase-1 protein expression, although in im-
munoreactive mature forms, does not necessarily corre-
spond to biological function. We previously reported the
presence of the precursor and intermediate, and furthermore
of the 20-kD mature, forms of caspase-1 in human vascular
SMCs (29). However, these cells lack caspase-1 processing
activity, due to a constitutively expressed caspase-1 inhibi-
tory activity. The demonstration of such inhibitory activity
furthermore explained the previous observation from our
group and others, that human vascular SMCs express IL-1b
upon stimulation but do not release this mediator (29).
Characteristics of the inhibitory activity resembled those
described here for the serpin PI-9 expressed by vascular
SMCs in vitro. Both are expressed constitutively and in a
cell-associated manner, and the reported molecular mass of
42 kD for PI-9 agreed with the expected molecular mass of
the caspase-1 inhibitory activity in SMCs (29, 41). PI-9 re-
portedly localizes in the cytosol (41), the compartment
where most caspase-1 resides (55), facilitating potential in-
teractions between these two mediators. Although the mo-
lecular mechanism of the PI-9–mediated inhibition of
caspase-1 exceeds the scope of this study, coprecipitation of
the enzyme using anti–PI-9 antibody established protein–
protein interactions, as also supported by the findings of An-
Figure 7. Differential expression of caspase-1 and PI-9 in human atherosclerotic lesions. Serial cryostat sections of frozen specimens of human nonath-
erosclerotic aorta (A–C) and carotid atheroma (D–G) were stained with (A and D) goat anti–human ICEP20 (1:100), (B and E) rabbit anti–human PI-9
(1:50), or (C and F) mouse anti–human IL-1b (1:100) antibody. (G) For colocalization of PI-9 (green) with caspase-1 (red), double-immunofluorescence
staining was performed. The asterisk indicates the lumen of the vessels. (H) Frozen tissue from nonatherosclerotic (Normal) as well as stable or unstable
atheromatous carotid plaques was analyzed by Western blotting using the anti–PI-9 (top) or anti–IL-1b (bottom) antibody. The positions of the molecu-
lar weight markers are indicated on the left (in kD). Analysis of tissue obtained from five nonatherosclerotic as well as five stable and seven vulnerable ath-
erosclerotic surgical specimens of different donors showed similar results.1542 Inhibition of Caspase-1 by the Serpin PI-9
nand et al. (44) using synthetic substrates. Furthermore, the
demonstration that optimal inhibition of IL-1b and IL-18
processing activity required the preincubation of the serpin
with the enzyme, rather than the substrate, suggested that
PI-9 interacts with caspase-1 rather than the cytokine. The
interaction with the serpin seems selective, since PI-9 did
not affect the enzymatic activities of another member of the
caspase family, caspase-3 (CPP-32), as also suggested by An-
nand et al. (44). Further hints regarding the molecular
mechanisms underlying the inhibition of caspase-1 emerge
from previous studies analyzing the inhibition of caspase-1
by a viral serpin, CrmA (35). CrmA rapidly inhibits caspase-1,
forming a tight complex with a low equilibrium constant
for inhibition. Thus, the viral serine proteinase inhibitor
CrmA, like a number of serpins, inhibits a nonserine pro-
teinase. Ray and colleagues further suggested that caspase-1,
a cysteine proteinase, shares substrate binding geometries re-
sembling those found in serine proteinases, and that it is the
substrate binding geometry, not the catalytic mechanism of
a proteinase, that dictates its reactivity with protein inhibi-
tors (37). The observations reported here agree with the ap-
plicability of this model to PI-9–caspase-1 interactions. The
finding that PI-9 affects caspase-1 activity at equimolar stoi-
chiometry and that complete inhibition of caspase-1 activity
requires a molar ratio of 1:5–1:8 of enzyme to inhibitor
resembles those obtained in experiments with CrmA (37).
In vivo in undiseased tissue, PI-9 levels clearly exceed those
of caspase-1, which lacks mature IL-1b. However, athero-
sclerotic lesions, characterized by chronic inflammation and
by the presence of mature IL-1b, exhibit decreased PI-9 ex-
pression. Our immunoprecipitation and antisense experiments
support the causal relationship between these observations.
The characterization of PI-9 as a human-derived, endog-
enous modulator of caspase-1, together with the differential
expression of the enzyme and its inhibitor at sites of chronic
inflammation in vivo, indicates the likely relevance of our
observations in physiological as well as pathological pro-
cesses. Our findings suggest that constitutive levels of PI-9
expression might limit caspase-1 activity, and represent a
novel endogenous antiinflammatory mechanism. However,
in diseased tissues (e.g., atheroma), augmentation of caspase-1
expression as well as imbalance between the enzyme and its
inhibitor favor caspase-1 activity and hence inflammation.
Because of the pivotal proximal role of IL-1b in the cyto-
kine cascade and the involvement of caspase-1 in apoptosis,
this imbalance between the enzyme and its inhibitor PI-9
could lower the threshold for activation of these two major
pathways (4, 56). The present observations should stimulate
further exploration of the role of this new antiinflammatory
pathway in atherosclerosis and other diseases.
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